Novel nanoplatform to enhance therapeutic effect for cancer

18 Aug 2021
Novel nanoplatform to enhance therapeutic effect for cancer

Cell membrane has attracted extensive attention worldwide and exhibited great application potential for drug delivery systems (DDSs).

However, along with the wide application of the cell membrane in DDSs, some limitations seriously limit cell membrane-based DDSs in clinical use, such as the complexity of preparation technology.

Therefore, it is highly important to develop methods for the preparation of biomimetic cell membranes in a simple and high-yield manner.

Recently, a collaborated team led by Professor Wu Zhengyan from Institute of Intelligent Machines, Hefei Institutes of Physical Science (HFIPS), Chinese Academy of Sciences (CAS), designed a simple self-assembled biomimetic cytomembrane-based nanoplatform (BMMP-Mn2+/Se/DOX) for mitochondrial targeted chemotherapy- and chemodynamic therapy of cancer.

Partners also include researchers from Institute of Health and Medical Technology (IHMT), HFIPS, and Binzhou Medical University.

The paper has been published in Journal of Nanobiotechnology.

This self-assembly biomimetic cytomembrane-based nanoplatform with pseudomonas geniculate cells as the natural source, which is further used to load some drugs capable of inducing chemotherapy and chemodynamic therapy.

There are two dominant advantages for this nanomedicine.

First, this nanoplatform shows minimal cytotoxicity and facilitates the internalisation of the drug more efficiently.

Second, the cascade reaction that can enhance the generation of reactive oxygen species is accelerated in cancerous cells by the nanomedicine, achieving precise tumour therapy by combining the chemo- and chemodynamic therapy.

Therefore, this self-assembly biomimetic cytomembrane-based nanoplatform synthesising nanotechnology opens a whole new set of opportunities for nanomedicine and biomedical engineering research.

Source: Hefei Institutes of Physical Science (HFIPS), Chinese Academy of Sciences (CAS)